Report: Achieving launch excellence in the challenging healthcare markets of today
|10th December 2018
Healthcare markets are becoming more competitive and complex. The sheer number of products coming off patent in the next five years, coupled with the growing healthcare spend and the number of players entering the healthcare space, mean it's clear pharma launches are becoming more challenging.
Adding to the pressure is the evolving networks of stakeholders who each have a differing needs and pain points and often communicate using novel digital channels.
However, while the market can seem overwhelming, these challenges provide pharma organisations with an opportunity to meet the unmet needs of customers through clearer and more targeted marketing, and more streamlined launches.
This in-depth report was created in collaboration with Pharma Intelligence and is based on our significant experience in this area. It features interviews with senior leaders and primary market research, as well as giving key recommendations for achieving launch success in challenging markets.
Download the white paper to learn:
- The characteristics of launch excellence evidenced by successful launches from the last two years
- How to transform the operating model to ensure market responsiveness
- How you can re-focus your brand planning to maximise success.
Delivering impactful customer engagements in COVID-19
|14th July 2020
Blue Latitude Health, and our parent company Fishawack Health, have developed exclusive intellectual property, processes and tools to ensure you’re engaging customers in the right way. View our service one-pagers below to find out how we can help solve your challenges whether you’re in a medical, brand, portfolio or an above brand role.
Top 5 tips for a multi-indication product launch
|8th July 2020
Senior Associate Consultant Sana Rahim and Senior Consultant Victoria Clark explain the lessons the team has learned from launching six different indications of an oncology product in an accelerated timeframe.
If our patients are diverse, why are clinical trials so white?
|22nd June 2020
Despite facing worse health outcomes, minority populations are often left out of clinical trials and miss the opportunity to participate in life-saving research. Associate Consultant Ling Song explores this issue and calls for the pharmaceutical industry to change its approach.